Skip to Content

Edurant FDA Approval History

FDA Approved: Yes (First approved May 20, 2011)
Brand name: Edurant
Generic name: rilpivirine
Dosage form: Tablets
Company: Tibotec Pharmaceuticals
Treatment for: HIV Infection

Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naïve).

Development Timeline for Edurant

DateArticle
May 20, 2011Approval FDA Approves New HIV Treatment Edurant (rilpivirine)
Jul 26, 2010Tibotec Pharmaceuticals Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.